Zura Bio stock: Zura Bio updates trial date. Guggenheim keeps USD 20 target for Zura Bio stock

Published on 10/24/2026 at 01:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TibuSHIELD completion moved to September 18, 2026. Zura Bio stock had a USD 20 target and last traded at USD 3.36 on October 23, 2026.

Trial timeline and valuation

TibuSHIELD's primary completion date was revised to September 18, 2026, in a trial update dated October 16, 2026.
The Phase 2 study enrolled 247 participants, with top-line results expected in the fourth quarter of 2026.
Zura Bio stock last traded at USD 3.36 on Nasdaq on October 23, 2026.
Guggenheim maintained a USD 20 target on October 7, 2026.
Cash stood at USD 205.0 million at the end of June 2026.

ZURA, KYG9TY5A1016, Illustration mit AI erstellt.

Zura Bio (ISIN KYG9TY5A1016) has moved the primary completion date for its 247-participant TibuSHIELD Phase 2 study to September 18, 2026, according to DataLookout. The update was posted on October 16, 2026, while Zura Bio stock had a USD 20 target from Guggenheim in an October 7, 2026 report covered by Investing.com.

Three dates shaped the pipeline

On February 26, 2026, Zura Bio priced a financing at USD 6.25 per share and reported gross proceeds of USD 143.75 million, as summarized by Zoomy. On August 11, 2026, the company reported second-quarter results and said TibuSHIELD enrollment had reached 247 patients, according to the Zura Bio investor-relations page. The October 16, 2026 trial-record update is the latest of the three events.

What does the trial date mean?

The revised completion date narrows the timetable for the key data event, but it does not establish clinical efficacy. The TibuSHIELD study evaluates tibulizumab over 16 weeks in adults with hidradenitis suppurativa, and the company describes the program as a Phase 2 test of a dual-pathway approach. Guggenheim's USD 20 target rests on a forecast of fourth-quarter 2026 TibuSHIELD results, while the firm also points to a planned systemic sclerosis readout in the first half of 2027, Investing.com reported.

Cash supports the next readout

Zura Bio held USD 205.0 million in cash and had zero debt at the end of June 2026, according to Simply Wall St. That balance gives the clinical timetable greater financial context, although the investment case still depends heavily on trial data rather than product revenue.

Upcoming reporting date

The next earnings report is scheduled for November 18, 2026, according to TradingView. The fourth-quarter 2026 TibuSHIELD readout remains the main clinical milestone described in the recent analyst coverage.

Stock price and investor view

Zura Bio's primary listing is Nasdaq, where the stock was last at USD 3.36 on October 23, 2026 at 4:00 p.m. ET. The same quote record places the 52-week range at USD 3.25 to USD 7.44 and the market capitalization at USD 322.0 million. For investors, the central tension is clear: the company has USD 205.0 million in cash, but the next major valuation test is the Phase 2 readout.

The further course of trading is shown by the continuously updated real-time quote of Zura Bio stock.